Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

A Phase I, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess Safety,Tolerability, Pharmacokinetics and Efficacy of MEDI-578, an Anti-NGF Monoclonal Antibody, After Single Ascending Doses in Male and Non-fertile Female Patients With Painful Osteoarthritis of the Knee

The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of MEDI-578, a monoclonal antibody, in patients with osteoarthritis of the knee. It will also be evaluated how MEDI-578 is absorbed and distributed through the body.

Inclusion Criteria:

• Patients with painful osteoarthritis of the knee.
• The pain from the knee must exceed pain experienced from any other condition.
• Patients must be willing and able to discontinue all current analgesic treatment.

Exclusion Criteria:

• Any other form of arthritis than osteoarthritis.
• Presence of neuropathic pain, or fibromyalgia, or wide spread chronic pain not related to osteoarthritis.
• Significant abnormalities on the clinical examination that may interfere with the study or present a safety risk to the patient, as judged by the investigator.